Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Hi, everyone, and welcome. I'm Najat Khan, Recursion's Chief R&D and Chief Commercial Officer and incoming CEO and President. Let's jump right in. Today is an important moment for Recursion, for our ...

In his 1960 book Theory and Design in the First Machine Age, the critic and historian Reyner Banham presciently noted a growing chasm between technological change and the capacity of designers to ...

The Eclipse Foundation's Jakarta EE Working Group has released Jakarta EE 11, the latest version of its enterprise Java platform, marking a significant step in modernizing enterprise Java development ...

Structure content for AI search so it’s easy for LLMs to cite. Use clarity, formatting, and hierarchy to improve your visibility in AI results. In the SEO world, when we talk about how to structure ...

ABSTRACT: In the context of the ongoing reform of educational evaluation, this study examines the implementation pathways of value-added assessment. Utilizing a horizontal comparative analysis of ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Prevent AI-generated tech debt with Skeleton ...

Recursion Pharmaceuticals (RXRX), a trailblazer in AI-powered drug discovery, recently acquired its competitor, Exscientia, in a strategic move that solidifies its leading position in the industry.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Recursion Pharmaceuticals Inc before investing. In this article, we go over a few ...